- Home
- EMD vs VALN Comparison
EMD vs VALN Comparison
Compare EMD & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMD
- VALN
- Stock Information
- Founded
- EMD 2003
- VALN 2012
- Country
- EMD United States
- VALN France
- Employees
- EMD N/A
- VALN N/A
- Industry
- EMD Finance/Investors Services
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EMD Finance
- VALN Health Care
- Exchange
- EMD Nasdaq
- VALN Nasdaq
- Market Cap
- EMD 581.9M
- VALN 645.1M
- IPO Year
- EMD N/A
- VALN 2021
- Fundamental
- Price
- EMD $10.10
- VALN $7.65
- Analyst Decision
- EMD
- VALN Strong Buy
- Analyst Count
- EMD 0
- VALN 3
- Target Price
- EMD N/A
- VALN $15.33
- AVG Volume (30 Days)
- EMD 248.5K
- VALN 43.2K
- Earning Date
- EMD 01-01-0001
- VALN 08-12-2025
- Dividend Yield
- EMD 10.25%
- VALN N/A
- EPS Growth
- EMD N/A
- VALN N/A
- EPS
- EMD N/A
- VALN N/A
- Revenue
- EMD N/A
- VALN $201,099,222.00
- Revenue This Year
- EMD N/A
- VALN $18.61
- Revenue Next Year
- EMD N/A
- VALN $25.07
- P/E Ratio
- EMD N/A
- VALN N/A
- Revenue Growth
- EMD N/A
- VALN 21.64
- 52 Week Low
- EMD $7.85
- VALN $3.62
- 52 Week High
- EMD $9.55
- VALN $8.66
- Technical
- Relative Strength Index (RSI)
- EMD 54.25
- VALN 73.87
- Support Level
- EMD $10.00
- VALN $7.53
- Resistance Level
- EMD $10.13
- VALN $8.50
- Average True Range (ATR)
- EMD 0.07
- VALN 0.36
- MACD
- EMD -0.02
- VALN 0.16
- Stochastic Oscillator
- EMD 45.45
- VALN 68.28
About EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.